Release Date: August 04, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- DaVita Inc DVA reported another positive quarter with adjusted operating income of $579 million and adjusted EPS of $4.02, in line with expectations.
- Treatment volume growth accelerated slightly faster than expected, driven by continued improvements in mortality, leading to increased confidence in achieving near the top end of the 25-50 basis points growth guidance.
- The transition of phosphate binders into the Medicare bundle has been successful, reducing reliance on less effective OTC options and improving patient access to clinically preferred therapies.
- DaVita Inc (DVA) has secured supply for expanded HD dialyzers, which are compatible with existing machines, allowing for broad deployment without significant capital investment and potentially improving patient outcomes.
- The company reaffirmed its full-year 2026 guidance for adjusted operating income and adjusted EPS, reflecting stable financial performance and strategic execution.
- DaVita Inc (DVA) continues to return capital to shareholders, repurchasing 2.2 million shares in Q2 and maintaining a consistent buyback program, with leverage within its target range.
- The minority investment in Elara Caring provides an opportunity to expand integrated care services, potentially enhancing patient care and creating new revenue streams.
Negative Points
- Revenue per treatment declined sequentially by approximately $2, reflecting lower commercial mix from declining ACA enrollment and lower phosphate binder revenue, with expectations of slightly negative RPT growth in the second half of 2026.
- The proposed 2027 ESRD payment update tracks below industry cost trends, potentially pressuring margins despite ongoing feedback to CMS.
- Patient care costs per treatment grew more than 3% year-to-date, above the expected range, though deceleration is anticipated in the back half of the year.
- The company experienced higher-than-expected miss treatments and fewer admits from closed Fresenius clinics, which partially offset volume gains.
- Commercial mix is expected to decline further, with a $40 million headwind in 2026 and an additional $70 million impact in 2027, driven by lower new patient mix from ACA subsidy expirations.
- The financial impact of deploying expanded HD technology is not expected to be significant until 2028, when mortality benefits may begin to materialize, delaying potential economic upside.
- G&A costs increased by $11 million sequentially, contributing to elevated cost per treatment growth in the first half of the year.
Q & A Highlights
Q: Despite growth in treatment, U.S. dialysis OI was relatively flat year-over-year while lapping a $45 million cyber headwind. Why aren't we seeing better leverage from treatment growth, and what drove the elevated cost per treatment in the quarter?
A: Joel Ackerman (CFO) explained that while enterprise OI was up about 5%, cost per treatment growth was elevated in the first half of the year, similar to revenue per treatment, creating an offset. Additionally, G&A growth continued at roughly 10% for the quarter, which were the primary items impacting U.S. dialysis margins.
Q: Can you provide more color on the volume trends? The two large dialysis providers combined appear to show negative same-store treatment growth. Is the industry shrinking, or are smaller chains taking share?
A: Javier Rodriguez (CEO) stated that DaVita's growth is driven by clinical performance that extends life, leading to increased treatment volume. He could not comment on the rest of the industry's performance. Joel Ackerman (CFO) added that the company's performance was clinically driven, with mortality and admits largely in line with expectations.
Q: With the deployment of expanded HD capability, what are the near-term economic implications beyond the potential for improved mortality?
A: Javier Rodriguez (CEO) outlined three categories: clinical benefits, operational simplicity (as switching dialyzers is straightforward), and supply confidence. He noted the financial impact is included in 2026 guidance and will not be significant for 2027 and beyond. Joel Ackerman (CFO) clarified that the impact is insignificant until the mortality benefit kicks in, which is not expected until 2028.
Q: Can you walk us through the process of patients transferring from commercial to government coverage due to ACA subsidy expiration? Are you seeing new patients come in on government plans, or existing patients dropping coverage?
A: Joel Ackerman (CFO) stated that DaVita is seeing both dynamics. The more sustained trend is new admits coming in at a lower commercial mix due to lower Qualified Health Plan (QHP) enrollment. This is expected to drive a $40 million headwind in 2026 and a $70 million headwind in 2027, which combines the annualizing effect of 2026 losses plus additional mix loss next year.
Q: What is the current occupancy rate of your centers, and how should we think about fixed cost leverage as treatment growth continues?
A: Joel Ackerman (CFO) noted that capacity utilization is running in the high 50s, up from a pre-COVID peak of about 65%. He cautioned that the marginal profit of a patient depends on the payer mix, with Medicare patients providing less marginal economics than commercial patients, making it difficult to pin down a single fixed-cost leverage number.
Q: The change in expectation from Fresenius clinic closures—is that just what you experienced in the quarter, or have you changed your full-year outlook for patient pickups?
A: Joel Ackerman (CFO) clarified that the pickup from the 100 Fresenius clinics they announced closing is now complete, as Fresenius has finished that effort. He does not expect this to change over the course of the year, and it is separate from other volume dynamics Fresenius has discussed.
Q: Have you secured enough supply of the new expanded HD dialyzers to transition all of your facilities, or just a portion?
A: Javier Rodriguez (CEO) confirmed that DaVita has secured enough supply to fulfill all physician demand for the transition. While the rollout will take time as the science is adopted, the company has the capacity to meet the full demand for the new dialyzers.
Q: Can you talk about the IKC business? How many more years can it contribute roughly $20 million to OI growth, and what is driving the improvement this year?
A: Joel Ackerman (CFO) stated there is no reason the growth can't continue for a while, driven by both margin expansion and increasing the number of lives and dollars under management. Javier Rodriguez (CEO) added that the current year's improvement is partly due to timing on revenue recognition, but the company is gaining confidence in managing total care costs and growing the business with more Medicare Advantage contracts.
Q: Given the stock price move, does the share repurchase pace change your capital allocation priorities for the rest of the year?
A: Javier Rodriguez (CEO) stated that capital allocation and the view on buybacks have been consistent throughout the year. The company was heavy on buybacks in Q1, totaling $785 million year-to-date, and the leverage ratio of 3.37x reflects the anticipated $200 million cash outlay for the Elara Caring investment that closed in July. There is no change in the buyback view.
Q: Are there any updates on M&A activity? Is it still primarily focused on international, or are there domestic assets like IKC you'd consider?
A: Javier Rodriguez (CEO) noted that the U.S. market is now highly consolidated, with only small "onesies and twosies" available. Future growth will come more from de novo clinic openings as the industry grows. The company will continue to evaluate acquisitions but there are not many available in the U.S. market.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
